Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Spike Pattern continues
View:
Post by 99942Apophis on Feb 25, 2021 9:52am

Spike Pattern continues

Last current price at 31 cents, I still see this spike moving into mid 30s this week with a strong possibility in this spike or the following spike to hit 43 cents.
Comment by Rumpl3StiltSkin on Feb 25, 2021 10:24am
Sounds good to me. :-)
Comment by winr88 on Feb 25, 2021 12:28pm
I was alerted to a company called Celsion CLSN. They claim an 88% success rating in their first phase trials treating ovarian cancer. They are in phase two now. If we can compare, then would this company give us a comparison of where Theralase could be going soon. CLSN is trading at $2.23 USD on the Nasdaq. They are also claiming success with SARS and covid Antigens.  Do you know anything ...more  
Comment by Rumpl3StiltSkin on Feb 25, 2021 1:15pm
Well they opened today at $2.44 and then traded down to about $2.15 they have 63M shares outstanding. So, divide that $2.15 by about 4.75 to get everhthing evened up with TLT and we are looking at around .45c US SP. So I hope TLT will be doing way better once our data comes out and we have Accelerated Approval from FDA. 
Comment by menoalittle on Feb 25, 2021 1:34pm
>> .45c US SP. So I hope TLT will be doing way better once our data comes out and we have Accelerated Approval from FDA.  yeah, as in, move that decimal point one place to the right.
Comment by tamarindo1 on Feb 26, 2021 10:58am
I guess that once again we're getting de-spiked.
Comment by 99942Apophis on Feb 26, 2021 11:53am
Yesterday heavy losses across the  board on N. American exchanges and today not as bad although it does add to the frustration. I doubt that my guess at a spike for this week will be in today's cards, let's just hope we can close around 29. The spike pattern won't disappear its still there and my uneducated guess for this spike to take the share price to mid 30s will still happen ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250